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Levoamphetamine and Dextroamphetamine: Differential Effect 
on Aggression and Hyperkinesis in Children and Dogs 
By L. Eugene Arnold, M.D., Vladimir Kirilcuk, M.D., PH.D., 
Samuel A. Corson, PH. D., and Elizabeth O'L. Corson, M.S. 
In laboratory experiments with hyperkinetic, untrainable dogs and in a comparison of levoamphetamine, 
dextroamphetamine, and placebo in children, levoamphetamine and dextroamphetamine were found to be 
approximately equal in calming an aggressive, hostile dog and in benefiting "unsocialized-aggressive" 
children; dextroamphetamine was more effective than levoamphetamine in calming "nervousness" and 
hyperactivity in dogs and in overanxious-hyperkinetic children. These data suggest that in the hyperkinetic 
syndrome, aggression and hostility may be benefited equally by levoamphetamine or dextroamphetamine 
via a dopaminergic mechanism, while anxiety and overactivity may be benefited significantly only by the 
dextro isomer via a norepinephrinergic mechanism. 
The plight of children with behavior and learning problems that often respond to stimulants 
by "paradoxical" calming has become well known under such names as "hyperkinetic syndrome," 
"minimal brain dysfunction," and "minimal brain damage." These and other grammatically singular 
appellations are bandied as if we believed these problems represented a single, homogeneous 
clinical entity (like pneumococcal pneumonia) that would uniformly respond to a prescribed 
treatment, if only we could find the treatment. However, those familiar with the syndrome readily 
admit its diversity of clinical pictures, probable diversity of etiology and pathogenesis, and even 
diversity of response to the highly touted stimulant therapy. 
At least two authors have recently attempted to clean up this diagnostic cesspool. Fish (1) 
has proposed criteria by which children who may respond favorably to stimulants could be 
assigned to one of three diagnostic categories: 308.0—hyperkinetic reaction (with immaturity, 
inadequacy, lability, and poor organization); 308.2— overanxious reaction ("nervousness" and 
possible overactivity with subjective distress, otherwise well-organized behavior); and 
308.4—unsocialized-aggressive reaction (aggressiveness and hostility with denial of feelings and 
personal responsibility, otherwise well-patterned behavior). These categories are reminiscent of 
Wender's "classical hyperactive," "neurotic," and "sociopathic" subsyndromes (2). 
One of the puzzling things about the hyperkinetic syndrome that raises serious questions 
about its being a homogeneous diagnostic entity is the individual variation in response to 
stimulants. It has long been known (3, 4) that sometimes dextroamphetamine helps a hyperkinetic 
child more than the racemic (dl) mixture does, and sometimes vice versa. In addition, some 
children are helped by methylphenidate (Ritalin) but not by amphetamine, and vice versa. 
Furthermore, while the majority of such children are helped by stimulants, a small percentage are 
actually made worse. The uncertainty concerning the practical clinical use of drugs for these 
children is underscored by recent attempts to introduce some prognostic guidelines. Barcai (5) has 
proposed a finger twitch test. Yoss and Moyer (6) have found that 25 percent of hyperkinetic and 
underachieving children have a narcoleptic-like electronic pupillogram that changes favorably with 
behavioral improvement on amphetamine. Knopp and associates (7) have found a correlation of 
approximately 0.6 (p<.01) between behavioral response to dextroamphetamine and changes in the 
extent of pupillary light reaction before and one-half hour after a test dose. 
The question naturally arises whether the differential drug effects may be correlated with 
the different diagnostic categories proposed by Fish (1) and Wender (2). Clinical pharmacological 
separation of the aggressive and "nervous" components of the hyperkinetic syndrome seems to be 
supported by data from pilot psychopharmacologic experiments with hyperkinetic, untrainable 
dogs in the Laboratory of Cerebrovisceral Physiology of the Department of Psychiatry, Ohio 
State University in Columbus. 
 
Category 
Dextroampheta
mine vs. 
Placebo 
Levoamphetamin
e vs. Placebo 
Dextroamphetamine vs. 
Levoamphetamine 
Psychiatrists' ratings    
Unsocialized-aggressive group p<.0001 p<.005 n.s. 
Overanxious-hyperkinetic group p<.03 n.s. p<.005 
Teachers' ratings    
Unsocialized-aggressive group p<.05 p<.05 n.s. 
Overanxious-hyperkinetic group p<.05 n.s. p<.05 
Parents' ratings    
Unsocialized-aggressive group p<.02 p<.02 n.s. 
Overanxious-hyperkinetic group n.s. n.s. n.s. 
Table 1 Comparison of Significant Differences Between Treatments with Dextroamphetamine, Levoamphetamine, 
and Placebo 
Dog Experiments 
Method and Results 
The four hyperkinetic, untrainable dogs used in this pilot study were previously reported on 
by Corson and associates (8,9). Most of the dogs were merely hyperkinetic, not particularly 
vicious. One of them, however, a cocker-beagle, was both hyperkinetic and aggressively hostile, 
providing a neat animal model for the constellation of symptoms seen in some aggressive 
hyperkinetic children. 
While aggressive behavior could be easily observed, even in the dog's home cage or 
kennel, the hyperkinetic traits could be best observed when a dog was placed on a Pavlovian stand, 
mildly restrained, and left alone in a soundproof chamber, as described by the Corsons elsewhere 
(10). Therefore, experiments were conducted in both settings. 
In cage experiments the aggressive hyperkinetic dog was given either 1- or 
d-amphetamine (10 mg. orally) on different occasions. Each time, amphetamines had a very 
pronounced effect: By approximately one hour the ordinarily vicious dog completely lost his 
aggressiveness. It was possible to take him out of the cage, walk him, pet him, and feed him a 
treat without danger of the experimenter's being bitten. 
Although both isomers were equally effective in suppressing aggression, the duration of 
effect was different: While d-amphetamine kept the dog quiet seven hours after administration, 
1-amphetamine lasted only about half as long. 
On the Pavlovian stand, "normal" dogs, after a few unsuccessful tries to escape, eventually 
give up fighting and tolerate the restraints. By contrast, "hyperkinetic" dogs immediately start 
thrashing, chewing equipment within reach, and trying to free themselves. This behavior would go 
on for indefinite numbers of experiments; they simply would not adapt to the experimental 
situation. 
Pavlovian-stand experiments in which both isomers were used were carried out on four 
hyperkinetic dogs, including the vicious one. The dosages varied from 2.5 to 40 mg. (.25 to 4.0 
mg./kg.). For each dog, elimination of all signs of hyperkinetic behavior required three to four 
times as much levoamphetamine as dextroamphetamine. The vicious dog, for example, required 
40 mg. of levoamphetamine to eliminate hyperkinesis as effectively as 10 mg. of 
dextroamphetamine did, even though his aggression and hostility were eliminated by 10 mg. of 
either isomer. 
This differential effect on hyperactivity paralleled the differential effect on appetite. The 
three dogs who showed anorexia did so with 1.0 mg./kg. of dextroamphetamine but required about 
three times that amount of levoamphetamine to produce anorexia. Unfortunately, 
dextroamphetamine had been tried before levoamphetamine in these exploratory experiments, so 
that tolerance cannot be ruled out as a source of the apparent difference in anorexogenic potency. 
Conclusions 
Thus, from pilot animal experiments in standardized laboratory settings, we have data 
suggesting that in hyperkinetic organisms: 1) levoamphetamine has a shorter duration of action 
than dextroamphetamine; 2) during the duration of maximal effect, levoamphetamine and 
dextroamphetamine seem to be approximately equal in their aggression-taming potency, but 
dextroamphetamine is three to four times as potent in calming "nervousness" and in producing 
anorexic effects; and 3) therefore, the beneficial effects of amphetamine on aggression and 
"nervousness" may operate through different biochemical mechanisms. 
Children 
Method and Design 
Encouraged by these findings in laboratory dogs, we returned to the raw data of a 
previously reported nine-week double-blind crossover comparison of levoamphetamine, 
dextroamphetamine, and placebo (11) that demonstrated the efficacy of levoamphetamine in 
hyperkinetic children. This study had only 11 subjects, but it offered reliable, quantitative, 
independent ratings by psychiatrists, teachers, and parents. Without being consciously aware of 
how each child fared comparatively on the dextroamphetamine and levoamphetamine ratings, we 
assigned each of the children to one of the three diagnostic categories advocated by Fish (1). This 
resulted in five diagnoses of unsocialized-aggressive reaction (308.4), four diagnoses of 
overanxious reaction (308.2), and two diagnoses of hyperkinetic reaction (308.0).i 
Because these last two groups were so small and because we were mainly interested in 
aggression as opposed to other manifestations of minimal brain dysfunction, we lumped those with 
overanxious reaction and those with hyperkinetic reaction together as the 
"overanxious-hyperkinetic" group for statistical comparisons on the three sets of ratings. 
Results 
Figure 1 shows the psychiatrists' ratings for the two groups; they are mainly based on 
weekly parental quantification of target symptoms. The three independent raters had an overall 
interrater reliability coefficient of 0.7734. Note that for the unsocialized-aggressive group 
levoamphetamine was rated as being almost as good as dextroamphetamine (difference not 
significant), and both of these active drugs were significantly better than placebo. In contrast, for 
the overanxious-hyperkinetic group the levoamphetamine was no better than placebo, even though 
dextroamphetamine was significantly better (see table 1). 
The same pattern emerged when the two groups were compared on the teachers' behavior 
rating scale (figure 2). Here we find that in the unsocialized-aggressive group levoamphetamine 
was actually rated slightly better than dextroamphetamine (difference not significant). Both active 
drugs were significantly better than placebo. Again we find that in the overanxious-hyperkinetic 
group levoamphetamine is rated as not significantly better than placebo, and dextroamphetamine 
as significantly better than either placebo or levoamphetamine (table 1). 
The parents' behavior checklist (figure 2) does not at first seem to show the same pattern. 
However, if we attend only to the differences that are statistically significant (p<.05 level), they 
do partially support the same pattern as the psychiatrists' and teachers' ratings. In the 
unsocialized-aggressive group both active drugs were rated as significantly better than placebo 
and not significantly different from each other. All differences for the overanxious-hyperkinetic 
group were not significant (see the results of comparison by one-tailed paired t test in table 1). 
 
Fig. 1. Comparison of Two Diagnostic Groups on Psychiatrists' Ratings of Drug Effect* with Placebo, 
Dextroamphetamine, and Levoamphetamine 
Individual factor scores for aggression, hyperactivity, and daydreaming-inattention on the 
pooled teachers' symptom ratings (11) likewise only partially showed the same pattern. The 
aggression factor showed comparable isomeric efficacy, as did the aggressive dog and the 
unsocialized-aggressive group. Further, the daydreaming-inattention factor showed a statistical gap 
in isomeric efficacy, as did the hyperkinetic dogs and the overanxious-hyperkinetic group. 
However, the hyperactivity factor showed comparable efficacy, a flaw in the pattern seen in the rest 
of the data. 
To rule out dosage variation as a source of the differences in efficacy, the average number 
of tablets given per day for each drug condition was tabulated by diagnosis (see table 2). The 
range of dosage is rather narrow, and what variation there is tends to dramatize the observed 
differences rather than question them. The clinicians had been instructed to optimize the dosage on 
each drug condition. Therefore an ineffective drug would tend to be given in higher dosages, as 
shown by the placebo doses. For the overanxious-hyperkinetic group, where levoamphetamine 
seemed ineffective, the drug was used in a dosage comparable to placebo, while 
dextroamphetamine, which was significantly more beneficial, was used in a much lower dose. 
For the unsocialized-aggressive group, where levoamphetamine seemed as beneficial as 
dextroamphetamine, levoamphetamine was used in lower doses. 
 
 Number of Tablets a Day
Medication 
Unsocialized- 
Aggressive Group
Overanxious-
Hyperkinetic 
Group
Placebo 6.9 7.0 
Dextroamphetamine* 6.5 5.7
Levoamphetamine* 5.7 6.9
* One tablet = 5 mg. of amphetamine sulfate. 
Table 2 Comparison of Two Diagnostic Groups on the Average Number of Tablets Used a Day for Each 
Drug Condition 
Discussion 
The teachers' ratings and the psychiatrists' ratings of weekly parental assessments of target 
symptoms in a double-blind crossover study on hyperkinetic children, as well as careful laboratory 
observations on a hyperkinetic aggressive dog, all suggest that aggressive, hostile behavior may be 
a distinct (if not separable) part of the hyperkinetic syndrome. It seems to be helped by 
levoamphetamine as much as by dextroamphetamine, in contrast to anxiety and overactivity, 
which appear to be helped significantly more by dextroamphetamine. The observations made on 
laboratory dogs demonstrate this contrast in the same organism; the data from the children's study 
show it from patient to patient. While the nonaggressive children who were merely hyperactive 
benefited significantly only from dextroamphetamine, the most aggressive children enjoyed 
approximately equal overall improvement when taking either levoamphetamine or 
dextroamphetamine. 
With regard to the latter, levoamphetamine, insofar as it has fewer "central side effects" 
than dextroamphetamine, may eventually become the drug of choice for the aggressive, hostile 
subgroup of hyperkinetic children who would be diagnosed by Fish's criteria as having 
"unsocialized aggressive reaction" (308.4). However, this is far from established by the data 
presented here, especially in view of: 1) the small numbers of children in the clinical study, 2) the 
retrospective nature of the assignment to diagnostic categories, 3) the failure of parents' ratings 
and pooled teachers' rating factors to confirm all the findings on psychiatrists' ratings and 
teachers' rating totals, and 4) the preliminary nature of the dog experiments. Further 
investigations on both animals and children are obviously needed. 
Whether levoamphetamine (and dextroamphetamine) may be useful in treating other kinds 
of aggression remains unclear at this point. Goldman, Lindner, and Dinitz at Ohio State 
University are initiating a double-blind comparison of placebo, levoamphetamine, 
dextroamphetamine, and imipramine in sociopathic convicts that may provide some information 
along this line. However, it may be argued that the aggression seen in sociopaths is not really a 
different kind; there is a suspicion that at least some sociopaths are hyperkinetic children grown 
up. 
The differential response to levoamphetamine, if upheld by further investigations, would 
tend to validate Fish's proposed diagnostic groupings for children with behavior disorders. Here, 
for the first time, we may have the beginnings of a diagnosis-treatment situation analogous to 
diagnosing pneumococcal pneumonia and treating it with penicillin rather than diagnosing 
Hemophilus influenzae pneumonia and treating it with ampicillin. Obviously, there remain many 
unanswered questions, some of which follow. 
1. It would be difficult to guess from the currently available data whether or not the "classical 
hyperkinetic" subgroup of hyperkinetic children should be lumped together with the 
"overanxious" group with regard to drug response, whether it would be more like the 
"unsocialized-aggressive" group, or whether it would be different from either. 
2. The place of learning disabilities in this scheme would need clarification. It is now known 
that some children who show primarily a learning disability without obvious behavior problems 
can also benefit from "stimulant" medication (12). Would such children in their drug response 
more closely parallel the unsocialized-aggressive group or the overanxious-hyperkinetic group, 
or would they constitute yet another group? 
3. The possibility of synergism between the optical isomers of amphetamine remains 
unexplored. The biochemical literature scarcely recognizes the possibility except for isolated, brief 
speculation (13). In the clinical literature the occasional superiority of racemic (dl) amphetamine 
over pure dextroamphetamine is reported without explanation (3, 4). It could result from either 
synergism or merely an additive effect since the racemic mixture is usually given in higher doses 
than pure dextroamphetamine. Two clinical observations more strongly suggest a possible 
synergism: 
A. Immediately upon completion of the double-blind, triple crossover comparison, six of the 11 
children were given racemic amphetamine in the same total daily dose as an interim medication 
until the code was broken in order to determine which of the isomers they had fared best on. Out of 
curiosity, the clinician involved (L.E.A.) did not tell the teachers that the study had ended and 
had them fill out an additional rating scale for the child's behavior the first week he was on 
racemic amphetamine. Five of the parents also cooperated by filling out an additional parent's 
rating. This "piggyback" experiment was thus blind only in regard to the teachers' ratings. The 
racemic amphetamine was reported to be the most effective of all four drug conditions by both 
teachers' and parents' checklists for two of the children, by the teachers' checklist alone for one 
child, and by the parents' checklist alone for one child. 
B. The other clinician in our original study (Keith R. McCloskey [11]) has since independently 
reported that he has found children who respond favorably to various ratios of dextro- and 
levoamphetamine but not to any other combination or to either isomer alone. 
 
Fig. 2. Teachers' and Parents' Blind Ratings* of Two Diagnostic Groups on Placebo, Dextroamphetamine, 
and Levoamphetamine 
Though both of these data are open to many criticisms, they do suggest that the potency 
relationships of the optical isomers of amphetamine may be more complex than has been 
previously realized and need to be further investigated both for their practical clinical applications 
and for their value in elucidating basic neurochemical phenomena. 
In a previous paper (11), the reasons were detailed for suspecting that, insofar as the levo 
isomer's efficacy matches that of the dextro isomer, amphetamine may help hyperkinetic children 
via a dopaminergic mechanism, whereas a wide disparity between the efficacies of the two 
isomers would suggest a norepinephrinergic mechanism. Briefly, Snyder and associates (13) 
showed that dextroamphetamine is ten times as potent as levoamphetamine in inhibiting 
catecholamine uptake by norepinephrinergic terminals and in eliciting locomotor activity in rats 
(believed to be norepinephrinergic) but that it is of comparable potency in inhibiting uptake by 
dopamine neurons or in eliciting stereotyped compulsive gnawing in rats, believed to be a 
dopaminergic-mediated syndrome. 
Further suggestive evidence for levoamphetamine's dopaminergic mode of action may lie in 
its apparent slow attainment of efficacy compared with dextroamphetamine on psychiatrists' 
ratings (see figure 1). Such slow-starting efficacy in hyperkinetic children has also been reported 
(14) for magnesium pemoline, believed to be strongly dopaminergic (15). This slow onset of 
action also recalls that of the major tranquilizers, whose antipsychotic properties are suspected to 
be inextricably linked to their typical extrapyramidal side effects (which are probably 
antidopaminergic). However, no conclusions should be drawn on the basis of these scanty data, 
especially since the temporal pattern seen on psychiatrists' ratings does not emerge on teachers' or 
parents' ratings. 
Supporting a dopaminergic mediation of aggression control, McKenzie(16) reported that 
apomorphine, believed to be a specific dopaminergic agonist, induces spontaneous aggression in 
male rats. Although this would seem to imply that dopaminergic drugs should exacerbate 
aggressive behavior, we must remember that some drugs have a paradoxical, reverse effect on 
some hyperkinetic children. At least, this finding supports the suspicion that dopaminergic 
receptors are "where the action is" for aggressive behavior. 
In this light the data presented here suggest the following hypothesis for further testing: that 
the unsocialized-aggressive subgroup of hyperkinetic children may benefit equally from either 
dextroamphetamine or levoamphetamine via a dopaminergic mechanism, in contrast to the 
overanxious and hyperkinetic children who are helped significantly by only dextroamphetamine via 
a norepinephrinergic mechanism. This hypothesis is far from established, but there does seem to be 
enough suggestive evidence to warrant further investigations along these lines. 
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i The unsocialized-aggressive group included two brothers with a chronic history of frequent serious 
fighting, stealing, and lying; a boy who had been expelled from two schools for misbehavior and had set a $1,200 
fire; and two other boys who were repeatedly suspended from school for fighting and other aggressive behavior and 
whose mothers asked for tranquilizers for themselves by the end of the boys' second week on placebo. One of these 
boys had thrown furniture at other children in the classroom. Both had a tendency to blame everyone else for their 
trouble; this sometimes verged on paranoia. Their parents seemed less adequate than those of the other two groups. 
The overanxious group was characterized by likability, subjective distress, anxiety, some insight, at least one 
loving, stable parent, and generally higher intelligence than the other two groups. 
The classical hyperkinetic group were also characterized by likability and at least one stable, loving parent. 
One of the children in this group was a postmeningitic kindergartener. Another carried the only diagnosis of mental 
retardation (borderline) in the study. His mother was concerned about his occasional bullying of smaller children, 
but this was not the most prominent manifestation of his problems, and the school did not complain about it. 
Because of his general disorganization and inadequacy, it seemed most appropriate to place him in this group rather 
than in the unsocialized-aggressive group. 
